Showing 1271-1280 of 21420 results for "".
- Oral Iptacopan in C3 Glomerulopathyhttps://reachmd.com/news/oral-iptacopan-in-c3-glomerulopathy/2487023/Key Takeaways At 6 months, iptacopan was associated with lower proteinuria than placebo, and the prespecified efficacy endpoint was met. Treatment-emergent adverse events occurred in both groups, were mostly mild or moderate, and no deaths, discontinua
- Late Outcomes After Pediatric Acute Kidney Injuryhttps://reachmd.com/news/late-outcomes-after-pediatric-acute-kidney-injury/2486992/Key Takeaways Pooled incidences after AKI were 17% for CKD, 6% for mortality, 20% for proteinuria, and 16% for hypertension. Across 23 comparator studies with follow-up from 3 months to 18 years, AKI was associated with higher odds of CKD and mortality
- AI-Supported Mammography Met Noninferiority For Interval Cancershttps://reachmd.com/news/ai-supported-mammography-met-noninferiority-for-interval-cancers/2486982/Key Takeaways AI-supported screening had a non-inferior interval cancer rate versus standard double reading. Sensitivity was higher with AI support, while specificity was the same in both groups. Investigators also described fewer interval can
- Do Recommended PAN Investigations Differentiate Cases From Controls?https://reachmd.com/news/do-recommended-pans-investigations-differentiate-cases-from-controls/2486972/Key Takeaways Abnormal laboratory findings were common in both groups, and recommended blood and throat testing did not distinguish PANS from idiopathic OCD and or tic disorder controls. In the PANS subgroup, CSF, MRI, and EEG findings were largely non
- Aging Cohort Analysis IDs Predictors of Stronger Epidermal Barrier Functionhttps://reachmd.com/news/aging-cohort-analysis-ids-predictors-of-stronger-epidermal-barrier-function/2486981/A large population-based analysis from the Baltimore Longitudinal Study of Aging identified several demographic factors associated with stronger skin barrier function, according to findings presented by Katrina Abuabara, MD, MSCE, and colleagues.
- TORPIDO 30/60 Trial Compares Initial Oxygen in Preterm Resuscitationhttps://reachmd.com/news/torpido-3060-trial-compares-initial-oxygen-in-preterm-resuscitation/2486971/Key Takeaways The primary composite outcome was similar between the two starting FiO2 groups. This was a multicountry randomized comparison across 31 maternity hospitals in 6 countries among infants due at 23 to 28 weeks' gestation. Escalation
- Inebilizumab vs Low-Dose Rituximab In NMOSDhttps://reachmd.com/news/inebilizumab-low-dose-rituximab-nmosd/2486946/Key Takeaways In NMOSD, inebilizumab was associated with fewer relapses and more favorable relapse-free survival and adjusted relapse burden over 12 months. Relapse-associated EDSS worsening was less frequent, and overall EDSS improvement favored inebi
- Darvadstrocel Findings in ADMIRE CD II Phase 3 Trialhttps://reachmd.com/news/darvadstrocel-admire-cd-ii-phase-3-trial/2486950/Key Takeaways A phase 3 double-blind placebo-controlled randomized trial enrolled adults with complex perianal fistulizing Crohn's disease after inadequate response to immunosuppressive agents or biologics and used standardized local procedures. Week 2
- Allergan Aesthetics Launches Skin Cancer Awareness Month Initiativehttps://reachmd.com/news/allergan-aesthetics-launches-skin-cancer-awareness-month-initiative/2486944/Allergan Aesthetics, an AbbVie company, launched a charitable initiative for Skin Cancer Awareness Month that will support The Skin Cancer Foundation through its Allē loyalty program. Throughout May, the company will donate $10 to The Skin Cancer Foundation for every new person who joins A
- CRT-Guided Resuscitation Improves Hierarchical Outcomes in Early Septic Shockhttps://reachmd.com/news/capillary-refill-time-early-septic-shock/2486923/Key Takeaways CRT-PHR was associated with a favorable 28-day hierarchical outcome versus usual care in early septic shock. Early resuscitation under CRT-PHR involved less fluid, more dobutamine use, lower central venous pressure and lactate, and more f